Interstitial Lung Disease Market Report 2026

Interstitial Lung Disease Market Overview

• Interstitial Lung Disease market size has reached to $2.09 billion in 2025 • Expected to grow to $3.09 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: Autoimmune Ailments Drive Growth In The Interstitial Lung Disease Market • Market Trend: Innovative Drug Development Initiatives To Improve Interstitial Lung Disease Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Interstitial Lung Disease Market?

Interstitial lung disease (ILD) refers to lung conditions that affect the interstitium, the tissue and the area surrounding the alveoli in the lungs. The interstitium is essential for maintaining the structural integrity and function of the lungs, as it supports gas exchange between the lungs and the bloodstream. The main types of drugs used for interstitial lung disease are oral corticosteroids, immune-suppressing, anti-fibrotic medication and others. Interstitial pneumonia, also known as non-infectious interstitial pneumonia, is a type of interstitial lung disease (ILD) that affects the interstitium, which is the tissue that surrounds and supports the air sacs (alveoli) in the lungs. They are indicated for the treatment of interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis and acute interstitial pneumonitis for adults and children. It is distributed by various channels such as hospital pharmacies, retail pharmacies and online pharmacies.

What Is The Interstitial Lung Disease Market Growth Forecast?

The interstitial lung disease market size is expected to see strong growth in the next few years. It will grow to $3.09 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growing aging population, rising diagnosis rates of interstitial lung disorders, increasing adoption of targeted anti-fibrotic drugs, expansion of research in novel ild therapies, improved patient screening and monitoring programs. Major trends in the forecast period include increasing emphasis on early and accurate ild diagnosis, growing adoption of anti-fibrotic therapies, rising focus on disease progression management, expansion of multidisciplinary care approaches, improved access to long-term ild treatment.

Global Interstitial Lung Disease Market Segmentation

1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs 2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis 3) By Application: Adults, Children 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone 2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil 3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib 4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies

What Is The Driver Of The Interstitial Lung Disease Market?

The rising incidence of autoimmune ailments is expected to propel the growth of the interstitial lung disease market going forward. Autoimmune ailments refer to medical conditions where the immune system erroneously attacks the body's healthy tissues and cells. A rising incidence of autoimmune ailments is a factor in the interstitial lung disease market by increasing the demand for ILD-related healthcare services, promoting research and development, and driving advancements in therapies and patient care. For instance, in September 2023, according to the Institute for Health Metrics and Evaluation, a US-based global health research center, the estimated global cases of rheumatoid arthritis is projected to increase to 31.7 million by 2050, indicating a significant rise in cases over this period. Therefore, the rising incidence of autoimmune ailments is driving the growth of the interstitial lung disease industry.

Key Players In The Global Interstitial Lung Disease Market

Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceuticals USA Inc., AstraZeneca plc, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Insmed Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health plc, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc

Global Interstitial Lung Disease Market Trends and Insights

Major companies operating in the interstitial lung disease market are focusing on product launch trends such as innovative therapies for various interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease, having scarring of lung tissue, leading to breathing difficulties and reduced oxygen transfer. For instance, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a Germany-based biopharmaceutical company has received FDA approval for BI 1015550 Therapy for the treatment of Idiopathic Pulmonary Fibrosis. BI 1015550 is an investigational oral therapy that inhibits phosphodiesterase 4B (PDE4B), with antifibrotic and anti-inflammatory effects aimed at slowing lung function decline in idiopathic pulmonary fibrosis (IPF).

What Are Latest Mergers And Acquisitions In The Interstitial Lung Disease Market?

In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.3 billion. With this acquisition, Merck & Co. intended to bolster the immunology drug pipeline as it faces the loss of exclusivity for some of its best-selling products over the next few years. Prometheus Biosciences Inc. is a US-based biotechnology company developing therapeutic and ancillary diagnostic products for managing immune-mediated illnesses, such as interstitial lung disease (ILD) linked to systemic sclerosis (SSc-ILD).

Regional Outlook

North America was the largest region in the interstitial lung disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Interstitial Lung Disease Market?

The interstitial lung disease market consists of revenues earned by entities by providing services such as individualized treatment plans and comprehensive support, pulmonary rehabilitation and oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial lung disease market also includes sales of prednisone, mycophenolate, azathioprine and cyclophosphamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Interstitial Lung Disease Market Report 2026?

The interstitial lung disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the interstitial lung disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.